Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study Alpaslan Ozgun, Fatma Mustafayev, Izzet Dogan, Sezai Vatansever, Melek Eryilmaz, Atike Erdogan, Gamze Ozturk, Murat Ayhan, Merve Turan, Mahmut Yildirim, Emre Hafizoglu, Oznur Bal, Pinar Tolunay, Ahmet Demirkazik, Eyyup Cavdar, Selcuk Seber, Gokcen Cevik, Hacer Demir, Ozgecan Dulgar, Mahmut Gumus, Emre Cakir, İlhan Hacibekirogullari, Ali Gokyer, Olcun Unal, Perihan Perkin, Teoman Sakalar, Ahmet Gulmez, Hakan Harputluoglu, Emin Elkiran, Elif Tasci, Ozlem Er, Sahin Lacin, Okan Kuzhan, Polat Olgun, Süleyman Temiz, Kerem Okutur, Bahiddin Yilmaz Molecular and Clinical Oncology, 2025 In recent years, significant success has been achieved in the treatment of metastatic melanoma with the use of immune checkpoint inhibitors (ICIs), and it resulted in a remarkable increase in patient survival. However, there are only a few studies reflecting daily practice outside of clinical trials. The present study aimed to evaluate the effectiveness and safety of ICI therapy in Turkish patients with metastatic melanoma, including those with poor prognostic factors such as advanced age and brain metastasis.<br />A retrospective analysis was conducted on 249 patients diagnosed with metastatic melanoma and treated with ICIs at 23 cancer centers in Turkey. The efficacy and safety of treatment were investigated, and prognostic factors were examined.<br />The mean age was 59 years, and 64% of patients were male. A total of 28% had BRAF mutation. A total of 22% of the patients were >70 years of age and 26% had brain metastases. The objective response rate with ICI therapy was 37.7%. The median overall survival (OS) was 61 months (95% CI 47‑74.9), and the median progression‑free survival was 7 months (95% CI 5.9‑8). Examining factors influencing overall survival, the difference in median OS was not statistically significant by sex and BRAF status, whereas there were statistically significant differences by age, objective response status, metastasis pattern, and presence of brain metastasis. Median OS was 35 months in patients >70 years when compared with 67 months in patients aged 70 years and younger (P=0.02). Median OS was 41 months in patients without objective response, whereas it could not be reached in patients with objective response (P<0.0001). Median OS was 35 months in patients with <em>de novo</em> metastatic disease compared with 78 months in patients with recurrent metastasis (P<0.0001). Moreover, median OS was 37 months in patients with brain metastasis in comparison with 67 months in patients without brain metastasis (P=0.006). Multivariate analysis revealed that absence of objective response, presence of <em>de novo</em> metastasis, and presence of brain metastasis were independent poor prognostic factors affecting survival. Grade 3‑4 immune‑related adverse effects were observed in 7.2% of patients, and treatment was discontinued due to adverse effects in 2.8% of patients. The present study demonstrated that real‑world data on ICI therapy in Turkish patients with metastatic melanoma may slightly differ from the results of other studies due to Turkey's conditions. Additionally, the present study, which included non‑clinical trial patients, revealed important prognostic factors.
Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review) Mehmet Teomete, Devrim Cabuk, Taner Korkmaz, Selcuk Seber, Ozge Ozturk, Birkan Aver, Atila Karaalp, Gul Basaran Oncology Letters, 2024 Breast cancer is most frequently diagnosed among women aged 65-74 years and the prevalence of comorbidities in elderly patients with breast cancer is 32.2%. In addition, polypharmacy is quite common in these patients. Understanding the interaction between breast cancer treatment modalities and comorbidities is important, particularly in elderly patients, as comorbidities affect the choice of appropriate treatment and are independent risk factors for survival. A total of three oral cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), palbociclib, ribociclib and abemaciclib, notably prolonged progression-free survival when combined with endocrine therapy (ET), compared with ET alone in patients with advanced breast cancer (ABC). The present review article therefore addressed the safety, tolerability and toxicity of CDK4/6i treatment in ABC management, compiled real-world data on how multiple clinical and pharmacological features may affect the choice of these drugs and provided practical recommendations for clinical approaches. Before starting treatment with CDK4/6i drugs, all ongoing medical conditions should be inventorized and re-graded, and examination should be performed for any additional disease that the patient may not be aware of. It is also important to obtain a detailed history of concomitant drugs, including prescription and over-the-counter drugs, vitamins, supplements and herbal products. In addition, patients should be advised to consult their oncologist before starting any new medication.
Prognostic values of various hematological variables as markers of systemic inflammation in metastatic lung cancer Selcuk Seber, Duygu Bayir, Tarkan Yetisyigit Journal of Cancer Research and Therapeutics, 2020 BACKGROUND: Chronic state of inflammation is an important factor in advanced cancer which is used by tumor cells for maintaining survival and growth. Hematological parameters such as neutrophil/lymphocyte ratio (NLR), thrombocyte/lymphocyte ratio (TLR), and lymphocyte/monocyte ratio (LMR) are reliable indicators of systemic inflammation. We aimed to elucidate the effect of hematological parameters and clinical features of patients on the prognosis of advanced-stage non-small cell lung cancer (NSCLC). METHODS: We included 102 Stage IV NSCLC patients who presented to the oncology clinic between 2010 and 2016. Pretreatment clinical parameters and NLR, TLR, and LMR were retrieved from the medical records. The cutoff values, calculated with receiver operating curve analysis, for NLR, LMR, and TLR were 2.5, 3, and 183, respectively. All patients were divided into two groups according to cutoff values and analyzed accordingly. RESULTS: Median overall survival and progression-free survival were 10 and 6 months, respectively. In univariate analysis, high NLR, high TLR, and low LMR were found to be significantly associated with survival. Among clinical parameters having eastern cooperative oncology group performance score 0-1, older age (≥70 years) single metastatic disease was prognostic. In multivariate Cox regression analysis, only the number of metastatic lesions and LMR were found to be independent predictors for survival. CONCLUSION: Among hematological parameters, only LMR was found to be an independent predictor of survival in patients with advanced-stage NSCLC.
Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line T Bilgen, S Seber, DY Sirin, T Yetisyigit Nigerian Journal of Clinical Practice, 2020 OBJECTIVE: Piperlongumine (PL) is an alkaloid derived from the edible pepper (Piper longum L) and it has been described to have various biologic activities including anticancer effects. Our aim in this study was to assess the cytotoxic role of PL on a cervical cancer cell line (HeLa) and to evaluate the effects of PL/doxorubicin and PL/paclitaxel combination therapies on apoptotic cancer cell death. MATERIAL AND METHODS: The cytotoxicity, IC50 doses by MTT assay confirmed by fluorescent imaging, and apoptotic cell rates by Annexin V staining using flow cytometry were determined for PL, doxorubicin, paclitaxel, and for their combinations. RESULTS: It was shown that the PL by itself induced the apoptosis in HeLa cells. PL in combination with doxorubicin and paclitaxel increased apoptotic cell death compared to either chemotherapeutic agent alone. CONCLUSION: We conclude that the PL inhibits cancer cell growth by inducing apoptosis and has a potential anticancer activity in cervical cancer, especially when combined with doxorubicin and paclitaxel.
Parathyroid adenoma, gastric adenocarcinoma, and intraabdominal schwannoma in one patient Gülşah Elbüken, Ersin Ergün, Özlem Öztürk, Erdoğan Selçuk Şeber, Mücahit Doğru, Ülkü Korkmaz Turkish Journal of Endocrinology and Metabolism, 2016 Intraabdominal schwannomas, which occur quite rarely, are usually benign tumors. They are often discovered coincidentally when abdominal scans are performed for other reasons. We also coincidentally detected an intraabdominal schwannoma in addition to primary hyperparathyroidism related to a parathyroid adenoma and a gastric adenoma which caused partial pyloric obstruction in a 69-year-old female patient who was admitted to our emergency room with vomiting while we were further investigating hypercalcemia that was found during laboratory workup. It is rare to diagnose multiple tumors concurrently in a single patient which are components of certain neuroendocrine syndromes themselves. It is more interesting to see a rare tumor such as intraabdominal schwannoma coexisting with a parathyroid adenoma that can be a component of multiple endocrine neoplasia syndromes. In the literature, there are few case reports of the coexistence of intraabdominal schwannomas with adenocarcinoma of the gastrointestinal tract. Here, we present an unusual case of intraabdominal schwannoma coexisting with parathyroid adenoma and gastic adenocarcinoma, all diagnosed in a single patient. To our best knowledge, this is the first case report of such a rare coexistence which makes it rather interesting.
Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting Selcuk Seber, Dilek Solmaz, Tarkan Yetisyigit Oncotargets and Therapy, 2016 PURPOSE: Antihormonal treatment is an effective therapy in the adjuvant setting. However, musculoskeletal pain is a common adverse effect encountered in patients receiving this treatment. We aimed to evaluate the risk factors for the development of antihormonal treatment-associated musculoskeletal pain (AHAMP) and its impact on the health-related quality of life (HRQOL). PATIENTS AND METHODS: A cross-sectional survey of 78 consecutive breast cancer patients receiving adjuvant antihormonal treatment for early-stage breast cancer in an academic medical oncology clinic was conducted. AHAMP was assessed by Health Assessment Questionnaire (HAQ) and 10 cm visual analog scale (VAS). HRQOL was assessed by self-administered short form 36 and Functional Assessment of Cancer Therapy-Breast subscale surveys. RESULTS: AHAMP was found to be present in 37 (47.7%) patients. In multivariate regression analysis, having a normal body mass index (<30 kg/m(2)), cigarette smoking, and low serum vitamin D level (20 ng/mL) were found to be independent risk factors. In HRQOL assessment, physical and mental scores were found to be significantly lower in patients with joint arthralgia. CONCLUSION: AHAMP has an adverse effect on the quality of life of breast cancer patients receiving adjuvant antihormonal treatment, and assessment of predictive factors is important for identification of patient groups at risk of developing this condition.
Protective effects of onion (Allium cepa) extract against doxorubicin-induced hepatotoxicity in rats Rafet Mete, Mustafa Oran, Birol Topcu, Meltem Oznur, Erdogan Selcuk Seber, Asuman Gedikbasi, Tarkan Yetisyigit Toxicology and Industrial Health, 2016 Background/aim:Doxorubicin (DOX) is a widely used and potent chemotherapeutic agent. However, serious dose-limiting toxicity through generation of free oxygen radicals is a commonly encountered clinical problem. The aim of the current study was to assess the protective role of onion ( Allium cepa) extract (ACE) against DOX-induced hepatotoxicity in rats.Method:A total of 24 rats were randomly divided into 3 equal experimental groups: (1) DOX; (2) ACE + DOX; and (3) control groups. ACE was given orally as 1 mL of fresh ACE juice for 14 consecutive days followed by DOX injection. DOX was injected intraperitoneally in a single dose of 30 mg/kg body weight to induce hepatotoxicity, and the rats were killed after 48 h from injection. Control group was given saline only.Results:In the ACE pretreated group (ACE + DOX), serum aspartate transaminase, alanine transaminase, and tissue malondialdehyde and glutathione levels were significantly lower, while superoxide dismutase and glutathione peroxidase were higher compared with the DOX group. The histopathological examination of liver specimens revealed parenchymal necrosis, proliferation of biliary duct in DOX group; while ACE pretreatment provided marked reduction in these changes.Conclusion:Our study indicates that pretreatment with ACE protects against DOX-induced hepatotoxicity due to the antioxidant properties of ACE. Further studies on efficacy of antioxidant treatment by ACE in DOX-mediated toxicity and underlying mechanisms would provide a better explanation.
Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy Selcuk Seber, Aylin Gonultas, Ozlem Ozturk, Tarkan Yetisyigit Oncotargets and Therapy, 2016 Recurrent squamous cell carcinoma of the skin is a rare but difficult to treat condition. Frequently, the disease presents itself in elderly patients with poor performance status and bearing many comorbidities, thus the decision to administer systemic chemotherapy becomes difficult to make. In addition, current chemotherapeutic protocols response rates are far from satisfactory. Recently cetuximab, a chimeric antibody against epidermal growth factor receptor, is increasingly being reported as an alternative treatment. We therefore report this case of a recurrent squamous cell carcinoma of the skin in an elderly woman with poor performance status and who had an excellent clinical response to single agent cetuximab therapy with complete resolution of the disease and minimal toxicity during the course of the treatment to provide evidence for future prospective clinical trials.
Management of Hypersensitivity in Oncology Practice: Risk Stratification, Phenotypic Markers, and Desensitization Protocols ÖF Elçiçek, Ö Yalıcı, E Çavdar, E Gedik, YG Bilen, İ Karaduman, ... 2026
The role of surgery type in breast cancer patients with recurrent breast cancer receiving neoadjuvant chemotherapy ES Şeber, Ö Yalıcı Adıyaman Üniversitesi Sağlık Bilimleri Dergisi 12 (1), 1-9 , 2026 2026
Beyond the Patient: The Association Between Patient Functional Disability, Caregiver Burden, and Mental Health in Oncology ÖF Elçiçek, E Çavdar, Ö Yalıcı, E Gedik, O Avcı, ES Şeber Bratislava Medical Journal, 1-9 , 2026 2026
Identifying high-risk groups for recurrence in endometrial cancer: The role of ESMO–ESGO–ESTRO risk classification ÖF Elçiçek, Ö Yalici, K Karaboyun, MB Şentürk, S Karabağ, E Çavdar, ... Journal of Cancer Research and Therapeutics 22 (1), 77-83 , 2026 2026
Inflammation‐Based Prognostication in Extensive‐Stage Small Cell Lung Cancer in the First‐Line Setting: The Advanced Lung Inflammation Index and the Others ES Şeber, ÖF Elçiçek, E Çavdar, Ö Yalıcı, YG Bilen, İ Karaduman, E Gedik, ... Asia‐Pacific Journal of Clinical Oncology 21 (6), 654-659 , 2025 2025 Citations: 5
Expression of gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 in breast cancer patients treated with neoadjuvant chemotherapy: a target … Y İriagac, M Oznur, E Çavdar, K Karaboyun, S Saray, O Avcı, ES Şeber Revista da Associação Médica Brasileira 71 (09), e20250507 , 2025 2025
Prognostic Value of Estrogen Receptor Co-activator AIB1 in Metastatic Breast Cancer Patients Treated with a Combination of Ribociclib and Letrozole E Cavdar, K Karaboyun, Y Iriagac, OF Elcicek, O Yalici, M Oznur, O Avci, ... Bratislava Medical Journal 126 (10), 2721-2727 , 2025 2025
The role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer T Yetişyiğit, K Karaboyun, Y İriağaç, E Çavdar, M Öznur, ES Şeber, ... Medicine 104 (39), e44743 , 2025 2025
Melatonin enhances everolimus efficacy in breast cancer by suppressing mTOR pathway activation and promoting apoptosis and mitochondrial function Ş Demirkesen, Y İriağaç, ES Şeber, C Aral BMC Pharmacology and Toxicology 26 (1), 100 , 2025 2025 Citations: 6
Real‑world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study A Ozgun, FNA Mustafayev, I Dogan, S Vatansever, MK Eryilmaz, ... Molecular and clinical oncology 22 (6), 51 , 2025 2025 Citations: 1
Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study N Majidova, AE Öztürk, R Çolak, Ö Yalıcı, MC İçli, B Köksal, M Arcagök, ... Turkish Journal of Clinics and Laboratory 16 (1), 123-130 , 2025 2025
Kas-İnvaziv mesane kanserinde neoadjuvan ve adjuvan kemoterapinin sağkalım üzerine etkinliği: Çok merkezli çalışma A Öztürk, R Çolak, M İÇLİ, B KÖKSAL, M Arcagök, S Kurşun, Y Çağlar, ... Turkish Journal of Clinics and Laboratory 16 (1) , 2025 2025
The role of stressful life events in breast cancer etiology Y İriağaç, E Çavdar, K Karaboyun, O Avcı, E Beyazyüz, ES Şeber Balıkesir Atatürk Şehir Hastanesi Tıp Dergisi 1 (1), 1-6 , 2024 2024 Citations: 2
Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions M Teomete, D Cabuk, T Korkmaz, S Seber, OF Ozturk, B Aver, A Karaalp, ... Oncology Letters 27 (4), 145 , 2024 2024 Citations: 9
Meme Kanserinde Sistemik Onkolojik Tedaviler G BAŞARAN, S SEBER Turkiye Klinikleri Plastic Surgery-Special Topics 13 (1), 37-43 , 2024 2024
Efficacy of neoadjuvant chemotherapy in lobular and rare subtypes of breast cancer E Seber, Y Iriagac, E Cavdar, K Karaboyun, O Avci, A Yolcu, S Gurdal, ... Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 34 (1) , 2024 2024 Citations: 5
Fertility desire and protection practices among Turkish young breast cancer patients treated with chemotherapy K Karaboyun, E Cavdar, Y Irıagac, SY Tacar, O Avci, S Seber Eurasian Journal of Medical Investigation 8 (1), 21 , 2024 2024 Citations: 1
Comparison of three equations for estimating glomerular filtration rate as predictors of cisplatin-related acute kidney injury in lung cancer patients with normal renal function K Karaboyun, Y İriağaç, E Çavdar, O Avci, ES Şeber Journal of Cancer Research and Therapeutics 20 (1), 144-149 , 2024 2024 Citations: 4
The role of interleukin-20 in paclitaxel-associated peripheral neuropathy in non-metastatic breast cancer patients receiving chemotherapy K Karaboyun, E Çavdar, Y İriağaç, A Yılmaz, A Çelikkol, O Avcı, ES Şeber Istanbul Medical Journal , 2023 2023 Citations: 1
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study O Avcı, Y İriağaç, E Çavdar, K Karaboyun, M Araz, T Şakalar, E Değerli, ... Journal of geriatric oncology 14 (8), 101604 , 2023 2023 Citations: 12
MOST CITED SCHOLAR PUBLICATIONS
Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients Ö Harmankaya, S Seber, M Yılmaz Renal failure 25 (3), 465-470 , 2003 2003 Citations: 72
Primary renal carcinoid: treatment and prognosis T Korkmaz, S Seber, D Yavuzer, M Gumus, NS Turhal Critical Reviews in Oncology/Hematology 87 (3), 256-264 , 2013 2013 Citations: 71
The effect of dual PPAR α/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients S Seber, S Ucak, O Basat, Y Altuntas Diabetes research and clinical practice 71 (1), 52-58 , 2006 2006 Citations: 70
Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials T Korkmaz, S Seber, G Basaran Critical reviews in oncology/hematology 98, 180-188 , 2016 2016 Citations: 68
Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: a multi-institutional retrospective analysis G Genestreti, M Tiseo, H Kenmotsu, W Kazushige, M Di Battista, ... Clinical lung cancer 16 (6), e223-e228 , 2015 2015 Citations: 68
Protective effects of onion ( Allium cepa ) extract against doxorubicin-induced hepatotoxicity in rats R Mete, M Oran, B Topcu, M Oznur, ES Seber, A Gedikbasi, T Yetisyigit Toxicology and industrial health 32 (3), 551-557 , 2016 2016 Citations: 63
Recurrent pericarditis as the initial manifestation of familial Mediterranean fever K Okutur1ABDEF, S Seber2BDEF, E Oztekin1BF, C Bes1BF, F Borlu1BF Med Sci Monit 14 (12), 141 , 2008 2008 Citations: 49
Visceral adipose tissue as an indicator of insulin resistance in nonobese patients with new onset type 2 diabetes mellitus O Basat, S Ucak, H Ozkurt, M Basak, S Seber, Y Altuntas Experimental and clinical endocrinology & diabetes 114 (02), 58-62 , 2006 2006 Citations: 42
Retrospective evaluation of totally implantable venous access port devices: early and late complications S Gurkan, S Seber, O Gur, T Yetisyigit, M Okan Donbaloglu, ... J buon 20 (1), 338-345 , 2015 2015 Citations: 40
After myocardial infarction carvedilol improves insulin resistance compared to metoprolol O Basat, S Ucak, S Seber, E Oztekin, Y Altuntas Clinical research in cardiology 95 (2), 99-104 , 2006 2006 Citations: 40
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis T Korkmaz, S Seber, U Kefeli, E Sari, M Canhoroz, B Oven, E Yildirim, ... Clinical and Translational Oncology 15 (7), 535-540 , 2013 2013 Citations: 29
Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer T Korkmaz, S Seber, K Okutur, G Basaran, F Yumuk, F Dane, T Ones, ... Biomarkers 18 (1), 88-94 , 2013 2013 Citations: 29
Breast cancer in young and very young women; Is age related to outcome? O Avci, SY Tacar, ES Seber, T Yetisyigit Journal of cancer research and therapeutics 17 (6), 1322-1327 , 2021 2021 Citations: 28
Prospective comparison of the value of CARG, G8, and VES-13 toxicity tools in predicting chemotherapy-related toxicity in older Turkish patients with cancer E Cavdar, Y Iriagac, K Karaboyun, O Avci, ES Seber Journal of Geriatric Oncology 13 (6), 821-827 , 2022 2022 Citations: 26
Clinical outcome of breast cancer patients with N3a (≥ 10 positive lymph nodes) disease: has it changed over years? G Basaran, C Devrim, HB Caglar, B Gulluoglu, H Kaya, S Seber, ... Medical Oncology 28 (3), 726-732 , 2011 2011 Citations: 23
Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes H Sargin, M Sargin, Y Altuntaş, AM Şengül, E Orbay, S Seber, S Uçak, ... Diabetes research and clinical practice 62 (2), 79-86 , 2003 2003 Citations: 23
Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line S Seber, DY Sirin, T Yetisyigit, T Bilgen Nigerian Journal of Clinical Practice 23 (3), 386-391 , 2020 2020 Citations: 19
Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting S Seber, D Solmaz, T Yetisyigit OncoTargets and therapy, 4929-4935 , 2016 2016 Citations: 18
Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities-single center experience D Cabuk, G Basaran, M Teomete, F Dane, T Korkmaz, S Seber, F Telli, ... Asian Pacific Journal of Cancer Prevention 15 (1) , 2014 2014 Citations: 16
Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer K Okutur, S Seber, T Korkmaz Journal of BUON 17, 669-676 , 2012 2012 Citations: 14
